Healthy Skepticism Library item: 6656

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Lexchin J, Vitry A.
Re: the promotion of Lincocin (lincomycin) and Dalacin C (clindamycin)
1996 Mar;

Abstract:

MaLAM does not believe that Upjohn’s response about its marketing of Lincocin and Dalacin C was adequate. There are still issues of safety, whether these drugs can be considered as first-line agents and Upjohn’s promotion standards.

Keywords:
*analysis/Upjohn/Dalacin C/Lincocin/antibiotics/company responses/quality of information/ safety & risk information/MaLAM/Medical Lobby for Appropriate Marketing/ATTITUDES REGARDING PROMOTION: INDUSTRY/ETHICAL ISSUES IN PROMOTION: COMPANY STANDARDS/EVALUATION OF PROMOTION: DRUG SAFETY/EVALUATION OF PROMOTION: GENERAL QUALITY OF INFORMATION/PROMOTION IN SPECIFIC THERAPEUTIC AREAS: ANTIBIOTICS/REGULATION, CODES, GUIDELINES: FEEDBACK TO COMPANIES